Owen E J, Siddle N C, McGarrigle H T, Pugh M A
Department of Obstetrics and Gynaecology, University College and Middlesex Hospitals, London, UK.
Br J Obstet Gynaecol. 1992 Aug;99(8):671-5. doi: 10.1111/j.1471-0528.1992.tb13853.x.
To assess the oestrogen concentrations and symptom relief obtained with 25 mg oestradiol implants.
Open, observational study.
Twelve symptomatic, post-menopausal women seen in a designated menopause clinic.
A 25 mg oestradiol pellet was inserted subcutaneously, blood samples were obtained before implantation and at regular intervals (2-4 weeks) until symptoms refused as hypoestrogenaemia developed.
Change in symptom score following implant treatment. Concentrations of oestrogens and their metabolites before and during low dose subcutaneous oestradiol therapy.
Ten of the 12 women had excellent symptom relief, associated with oestradiol concentrations in the follicular range for between 28 and 35 weeks. The ratio of circulating oestrogen metabolites remained physiological, despite the oestradiol concentrations being substantially higher on treatment.
We suggest that 25 mg pellets should be used as the initial dose for subcutaneous oestrogen treatment, and a combination of return of symptoms and weeks since insertion used to judge the timing of reimplantation.
评估使用25毫克雌二醇植入物后的雌激素浓度及症状缓解情况。
开放性观察研究。
在指定更年期诊所就诊的12名有症状的绝经后女性。
皮下植入一颗25毫克的雌二醇药丸，在植入前及之后定期（2 - 4周）采集血样，直至因出现低雌激素血症症状消失。
植入治疗后症状评分的变化。低剂量皮下雌二醇治疗前及治疗期间雌激素及其代谢产物的浓度。
12名女性中有10名症状得到显著缓解，且在28至35周期间雌二醇浓度处于卵泡期范围。尽管治疗期间雌二醇浓度大幅升高，但循环雌激素代谢产物的比例仍保持生理水平。
我们建议将25毫克药丸作为皮下雌激素治疗的初始剂量，并结合症状复发情况及植入后的周数来判断再次植入的时机。
